[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634098":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":65,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":86,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Icahn School of Medicine at Mount Sinai","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients indicated for atrial arrhythmia ablation",null,"All patients will receive standard of care treatment.",[13],"Device: FARAWAVE Pulsed Field Ablation Catheter",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","FARAWAVE Pulsed Field Ablation Catheter","The FARAWAVE Pulsed Field Ablation (PFA) Catheter is a component of the FARAPULSE PFA System. The FARAWAVE Catheter is an over-the-wire, multi-electrode catheter designed to deliver PFA energy to the distal section for cardiac ablation. The FARAWAVE Catheter is indicated for: 1) the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF) 2) the isolation of pulmonary veins and the posterior wall in the treatment of drug-refractory, symptomatic Persistent Atrial Fibrillation (episode duration less than one year) This device is FDA approved.",[9],[21],{"name":22,"affiliation":5,"role":23},"Vivek Reddy, MD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Devin Chamberlain","CONTACT","(646) 984-1049","devin.chamberlain@mountsinai.org",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},"Betsy Ellsworth, MSN, ANP","Betsy.ellsworth@mountsinai.org",[34,51],{"facility":35,"status":36,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Mount Sinai Hospital","RECRUITING","New York","10030","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-74.00597,40.71427,{"lat":45,"lon":44},[48,49],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":50,"role":23,"phone":10,"phoneExt":10,"email":10},"Joshua Lampert, MD",{"facility":52,"status":36,"city":53,"state":54,"zip":55,"country":39,"countryCode":40,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Valley Health System","Winchester","Virginia","22601",{"type":42,"coordinates":57},[58,59],-78.16333,39.18566,{"lat":59,"lon":58},[62],{"name":63,"role":27,"phone":10,"phoneExt":10,"email":64},"Lauren Peterson","lpeterso@valleyhealthlink.com",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Vivek Reddy","Director, Cardiac Arrhythmia Service",[70],{"name":71,"class":72},"Boston Scientific Corporation","INDUSTRY","100634098","represent-pf-registry-100634098",false,"NCT07535268","REPRESENT-PF Registry","Prospective Multicenter Registry on the Clinical Outcomes and Safety of PFA for Atrial Fibrillation in Underrepresented Minorities (REPRESENT-PF Registry)","REPRESENT-PF","Inclusion Criteria:\n\n* All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.\n* De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.\n* Able and willing to participate in baseline and follow up evaluation over the study period\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan\n* Long standing persistent AF (AF \\> 1 year duration)\n* Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry\n* Any known contra-indication to ablation procedure at the discretion of the investigator","ALL","18 Years",{"count":84,"type":85},275,"ESTIMATED","12 Months","OBSERVATIONAL","This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.",[90,91],"Persistent Atrial Fibrillation","Paroxysmal Atrial Fibrillation",[91,90,93],"Pulsed Field Ablation","2026-04-09",{"date":96,"type":97},"2026-04-17","ACTUAL",{"date":99,"type":97},"2026-03-30",{"date":101,"type":85},"2028-03-01",{"name":67,"class":6},2]